Chinese Firms Launched Fewer Global Phase III Programs With US Sites In 2025

Licensing Bonanza Saw Some Partners Take Over Trials

 
• By Dexter Jie Yan
  
perspectives 2026
2025 saw Chinese drug makers act as sole sponsor for fewer global Phase III clinical trials with US sites than in the previous year. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip Perspectives

More from Clinical Trials